Healthcare information software solutions provider Merge Healthcare Incorporated MRGE recently launched its ground-breaking mobile app – Study Connect – to facilitate clinical researchers.
Researchers in possession of Merge’s eClinicalOS (eCOS) cloud-based system can now perform a wide range of clinical trial management functions using this app on their iOS-based mobile devices.
This multi-functioning app will allow researchers to manage randomized data, inventory, unblind individual subjects in trial and stay connected with real-time customized notifications, among several other significant operations.
Per management, the app will make it possible for researchers to effectively perform a clinical trial, merely through the use of their tablets and smartphones.
With studies being conducted in large numbers at multiple sites across varied time zones, it becomes extremely difficult for researchers to adequately track research variables and respond appropriately in real time. With the Study Connect app, eClinical OS researchers will now be able to interact in real time, thanks to cloud computing, thus saving unnecessary delay in trial accomplishments.
Moreover, according to management, only a handful of mobile clinical research apps have been launched in the market so far, of which almost all are limited solely to patient-reporting functions.
Study Connect is currently available on the App Store and is supported on both iPads and iPhones. Management is eagerly awaiting user response to the launched version, based on which its R&D team will come up with further improvements.
While technology is becoming an indispensable part of people’s lives, we feel that such applications will enhance business opportunities of Merge’s services. We are also encouraged by the Transparency Market Research report which states that, the global IT-enabled healthcare market is estimated to reach $210.32 billion in 2020, with a CAGR of growth of 11.8% from 2014 to 2020.
This encourages us to believe that Merge’s newly launched Study Connect app, combined with the company’s market potential, will help it soon capture considerable share in this market; going forward.
Currently, the stock carries a Zacks Rank #2 (Buy). Some other medical stocks that warrant a look are Actelion Ltd. ALIOF, Gilead Sciences Inc. GILD and Illumina Inc. ILMN. All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment